Adial Pharmaceuticals has renewed CEO Cary Claiborne's contract through a new three-year Amended and Restated Employment Agreement, effective December 5, 2024. The agreement supersedes his previous contract from December 2021 and subsequent amendment from August 2022.Under the new terms, Claiborne's bonus target has been increased to 50% of his base salary, subject to achievement of board-determined objectives. Additionally, he received a stock option grant for 350,000 shares under the company's 2017 Equity Incentive Plan, which will vest monthly on a pro rata basis over 36 months.

Adial Pharmaceuticals has renewed CEO Cary Claiborne's contract through a new three-year Amended and Restated Employment Agreement, effective December 5, 2024. The agreement supersedes his previous contract from December 2021 and subsequent amendment from August 2022.Under the new terms, Claiborne's bonus target has been increased to 50% of his base salary, subject to achievement of board-determined objectives. Additionally, he received a stock option grant for 350,000 shares under the company's 2017 Equity Incentive Plan, which will vest monthly on a pro rata basis over 36 months.